<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102244</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-09-35</org_study_id>
    <nct_id>NCT01102244</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy and safety of Tobradex ST
      compared to AzaSite in the treatment of moderate to severe chronic blepharitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global sign and symptom score for blepharitis</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>Tobradex ST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tobramycin 0.3%, dexamethasone 0.05%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azasite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>azithromycin 1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobradex ST</intervention_name>
    <description>tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days</description>
    <arm_group_label>Tobradex ST</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azasite</intervention_name>
    <description>azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days</description>
    <arm_group_label>Azasite</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have diagnosis of moderate to severe chronic blepharitis defined by a minimum score of
             at least &quot;1&quot; for one of the lid signs, one of the conjunctival signs, and one of the
             symptoms in at least one eye

          -  Have a minimum global score (the total signs and symptoms score) of 5 in the same eye
             qualifying.

        Exclusion Criteria:

          -  Have known sensitivity or poor tolerance to the test article (tobramycin,
             dexamethasone, azithromycin) or its components or any therapy associated with the
             trial

          -  Have a history of ocular surgical intervention within six (6) weeks prior to Visit 1
             or during the study

          -  Have any ocular infections (bacterial, viral or fungal) - active ocular inflammation
             (i.e. follicular conjunctivitis, iritis) or preauricular lymphadenopathy, other than
             blepharitis

          -  Have worn contact lenses in the 72 hours prior to visit 1 and for the duration of the
             study

          -  Are currently taking any medication known to cause ocular drying that has not been on
             a stable dose for at least 30 days

          -  Have used any topical ocular or systemic antibiotics within 7 days of enrollment.
             Stable (greater than 1 month prior to enrollment) use of topical antibiotics on the
             face (except around the eyes) for dermatologic conditions is allowed. Dose must
             continue unchanged for duration of study

          -  Have used any topical ocular - aerosolized/nebulized - or systemic corticosteroid
             agents within 14 days of enrollment. Stable (greater than 1 month prior to enrollment)
             use of inhaled (using mouthpiece) and nasal corticosteroids and topical dermal
             steroids (except around the eyelids) are allowed. Dose must continue unchanged for the
             duration of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ora</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blepharitis</keyword>
  <keyword>moderate to severe chronic blepharitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

